(D-Trp12,Tyr34)-pTH (7-34) amide (bovine) 

(D-Trp12,Tyr34)-pTH (7-34) amide (bovine) is a potent and competitive antagonist of parathyroid hormone (PTH), with a K_i of 69 nM in bovine renal cortical membrane. (D-Trp12,Tyr34)-pTH (7-34) amide (bovine) can be used for growth and development regulation^[1][2].

Ki: 69 nM (PTH)^[1]

(D-Trp12,Tyr34)-pTH (7-34) amide (0.05-10 μM) causes a concentration-dependent inhibition of PTHrP or PTH-stimulated cAMP formation in opossum kidney (OK) cells^[2].
(D-Trp12,Tyr34)-pTH (7-34) amide (0.1-10 μM) attenuates inhibition of Nap_iT promoted by 1 nM of either PTHrP or PTH^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

(D-Trp12,Tyr34)-pTH (7-34) amide (1 mg/mL once, 0.1 mg/mL for 6 h; i.v.) has no significant effect on serum calcium levels in hypercalcemic athymic nude mice bearing a human squamous cell carcinoma of the lung^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

3625.25

C₁₆₅H₂₅₁N₄₉O₄₀S₂

118102-98-0

固体

White to off-white

Phe-Met-His-Asn-Leu-{d-Trp}-Lys-His-Leu-Ser-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Tyr-NH2

FMHNL-{d-Trp}-KHLSSMERVEWLRKKLQDVHNY-NH2

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

• [1]. Goldma ME, et, al. A new highly potent parathyroid hormone antagonist: [D-Trp12,Tyr34]bPTH-(7-34)NH2. Endocrinology. 1988 Nov; 123(5): 2597-9.  [Content Brief]

  [2]. Pizurki L, et, al. Inhibition by (D-Trp12,Tyr34)bPTH(7-34)amide of PTH and PTHrP effects on Pi transport in renal cells. Am J Physiol. 1990 Aug; 259(2 Pt 2): F389-92.  [Content Brief]

  [3]. Kukreja SC, Inactivation by plasma may be responsible for lack of efficacy of parathyroid hormone antagonists in hypercalcemia of malignancy. Endocrinology. 1994 May; 134(5): 2184-8.  [Content Brief]